[The effect of the emergent vaccination using DTP vaccine to control the outbreak of pertussis]

Area of Science:

• Immunology
• Epidemiology
• Pediatrics

Background:

• Pertussis outbreaks pose a significant public health risk, particularly in unvaccinated or under-vaccinated populations.
• The Diphtheria, Tetanus, and Pertussis (DTP) vaccine is a primary tool for preventing pertussis, but its efficacy in outbreak control through emergent vaccination requires further study.

Purpose of the Study:

• To evaluate the safety and efficacy of emergent DTP vaccination in controlling a pertussis outbreak.
• To assess the impact of emergent DTP vaccination on pertussis antibody titers and clinical outcomes in exposed children.

Main Methods:

• A randomized controlled trial was conducted with 4-6 year old children exposed to pertussis.
• Children were randomly assigned to receive either the DTP vaccine (n=76) or a placebo (n=72).
• Outcomes measured included adverse reactions, pertussis antibody titers (GMT), attack rates, and clinical symptoms within 21 days post-vaccination.

Main Results:

• No severe adverse reactions were observed in the DTP-vaccinated group.
• GMT antibody levels for pertussis increased significantly (18.14-fold at 2 weeks, 4.73-fold at 3 months) post-vaccination.
• No significant differences in attack rates or clinical symptoms were found between the DTP and placebo groups within 21 days.
• A protection rate of 62.11% was observed three months after emergent vaccination.

Conclusions:

• Emergent DTP vaccination is a safe intervention for children during a pertussis outbreak.
• While antibody titers increase, emergent DTP vaccination did not show immediate protection against symptomatic pertussis within 21 days in this study.
• The study suggests a potential benefit of emergent vaccination in controlling pertussis outbreaks, warranting further investigation into longer-term protection.